CVS Health Corporation $CVS Shares Sold by BW Gestao de Investimentos Ltda.

BW Gestao de Investimentos Ltda. lowered its stake in CVS Health Corporation (NYSE:CVS) by 56.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 310,000 shares of the pharmacy operator’s stock after selling 400,000 shares during the quarter. CVS Health comprises about 1.0% of BW Gestao de Investimentos Ltda.’s portfolio, making the stock its 15th biggest holding. BW Gestao de Investimentos Ltda.’s holdings in CVS Health were worth $23,371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in shares of CVS Health in the 2nd quarter worth approximately $1,358,698,000. Invesco Ltd. increased its holdings in CVS Health by 15.3% in the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after purchasing an additional 3,118,626 shares during the last quarter. Vanguard Group Inc. raised its position in CVS Health by 1.7% in the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after purchasing an additional 2,063,737 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in CVS Health by 153.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,105,827 shares of the pharmacy operator’s stock worth $214,240,000 after purchasing an additional 1,878,217 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its stake in CVS Health by 2,675.7% during the second quarter. Panagora Asset Management Inc. now owns 1,116,742 shares of the pharmacy operator’s stock worth $77,033,000 after purchasing an additional 1,076,509 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Price Performance

CVS stock opened at $78.25 on Tuesday. The business’s 50-day moving average is $78.46 and its two-hundred day moving average is $77.70. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. The firm has a market capitalization of $99.55 billion, a P/E ratio of 56.70, a P/E/G ratio of 0.81 and a beta of 0.49. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $85.15.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is presently 192.75%.

Analysts Set New Price Targets

CVS has been the subject of a number of research reports. Truist Financial set a $100.00 price objective on CVS Health in a research note on Wednesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 29th. Barclays increased their price target on shares of CVS Health from $87.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Finally, Mizuho raised their price objective on shares of CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Nineteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.91.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.